-
公开(公告)号：US08575312B2
公开(公告)日：2013-11-05
申请号：US13446254
申请日：2012-04-13
申请人： Dirk Behrens , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
发明人： Dirk Behrens , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
IPC分类号： C07K14/00
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
摘要翻译： 公开了一种新鉴定的分泌型分子，本文称为“单核细胞，粒细胞和树突细胞集落刺激因子”（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。 还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。 另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。 还公开了将多肽及其活性片段用于治疗各种疾病（包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性妊娠损失）的方法。
-
公开(公告)号：US20110003384A1
公开(公告)日：2011-01-06
申请号：US12370559
申请日：2009-02-12
申请人： Dirk BEHRENS , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
发明人： Dirk BEHRENS , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
IPC分类号： C12N5/071
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
摘要翻译： 公开了一种新鉴定的分泌型分子，本文称为“单核细胞，粒细胞和树突细胞集落刺激因子”（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。 还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。 另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。 还公开了将多肽及其活性片段用于治疗各种疾病（包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性妊娠损失）的方法。
-
公开(公告)号：US08178109B2
公开(公告)日：2012-05-15
申请号：US12370559
申请日：2009-02-12
申请人： Dirk Behrens , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
发明人： Dirk Behrens , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
IPC分类号： A61K39/00
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
摘要翻译： 公开了一种新鉴定的分泌型分子，本文称为“单核细胞，粒细胞和树突细胞集落刺激因子”（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。 还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。 另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。 还公开了将多肽及其活性片段用于治疗各种疾病（包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性妊娠损失）的方法。
-
公开(公告)号：US20120258071A1
公开(公告)日：2012-10-11
申请号：US13446254
申请日：2012-04-13
申请人： Dirk Behrens , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
发明人： Dirk Behrens , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
摘要翻译： 公开了一种新鉴定的分泌型分子，本文鉴定为单核细胞，粒细胞和树突细胞集落刺激因子（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。 还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。 另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。 还公开了将多肽及其活性片段用于治疗各种疾病（包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性妊娠损失）的方法。
-
公开(公告)号：US20070264277A1
公开(公告)日：2007-11-15
申请号：US11632319
申请日：2005-07-21
申请人： Dirk Behrens , Elizabeth Bosch , Stephen Doberstein , Robert Halenbeck , Kevin Hestir , Min Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin Wong , Ge Wu , Aileen Zhou
发明人： Dirk Behrens , Elizabeth Bosch , Stephen Doberstein , Robert Halenbeck , Kevin Hestir , Min Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin Wong , Ge Wu , Aileen Zhou
IPC分类号： A61K39/00 , A61K38/00 , C07H21/00 , C07K14/00 , C07K16/18 , C12N15/00 , C12N15/87 , C12N5/06 , C12P1/00 , G01N33/53
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
摘要翻译： 公开了一种新鉴定的分泌型分子，本文称为“单核细胞，粒细胞和树突细胞集落刺激因子”（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。 还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。 另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。 还公开了将多肽及其活性片段用于治疗各种疾病（包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性妊娠损失）的方法。
-
公开(公告)号：US07982014B2
公开(公告)日：2011-07-19
申请号：US12652720
申请日：2010-01-05
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
公开(公告)号：US20130065276A1
公开(公告)日：2013-03-14
申请号：US13227398
申请日：2011-09-07
申请人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
-
8.发明申请公开(公告)号：US20110281302A1
公开(公告)日：2011-11-17
申请号：US13157712
申请日：2011-06-10
申请人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
公开(公告)号：US08580936B2
公开(公告)日：2013-11-12
申请号：US13227398
申请日：2011-09-07
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
10.发明申请公开(公告)号：US20120301921A1
公开(公告)日：2012-11-29
申请号：US13438638
申请日：2012-04-03
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.066 秒)
